HIGH GRADE OVARIAN SEROUS ADENOCARCINOMA
Clinical trials for HIGH GRADE OVARIAN SEROUS ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new HIGH GRADE OVARIAN SEROUS ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for HIGH GRADE OVARIAN SEROUS ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo therapy targets Hard-to-Treat recurrent cancers
Disease control OngoingThis early-phase trial studies two drug combinations (olaparib plus vistusertib or olaparib plus capivasertib) in people with recurrent endometrial, triple-negative breast, ovarian, or related cancers. The main goal is to find the safest dose and understand side effects. About 15…
Matched conditions: HIGH GRADE OVARIAN SEROUS ADENOCARCINOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 03:30 UTC
-
New drug shows promise in shrinking ovarian tumors before surgery
Disease control OngoingThis early-phase trial is testing the drug olaparib in 15 people with newly diagnosed BRCA-mutant ovarian, fallopian tube, or peritoneal cancer. Participants take olaparib for two cycles before their planned surgery to see if it can shrink tumors and is safe. The goal is to find …
Matched conditions: HIGH GRADE OVARIAN SEROUS ADENOCARCINOMA
Phase: EARLY_PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 03:28 UTC
-
New drug combo targets recurrent ovarian and endometrial cancers
Disease control OngoingThis early-phase study tests a combination of two oral and intravenous drugs (niraparib and copanlisib) in people whose endometrial, ovarian, peritoneal, or fallopian tube cancer has returned. The main goal is to find the safest dose and understand side effects. About 31 particip…
Matched conditions: HIGH GRADE OVARIAN SEROUS ADENOCARCINOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 03:14 UTC